Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.

被引：0
|
作者：
Vandenberg, Cassandra J. [1 ]
Ho, Gwo-Yaw [1 ]
Nesic, Ksenija [1 ]
Swisher, Elizabeth M. [2 ]
Grimmond, Sean M. [3 ]
Wakefield, Matthew J. [1 ]
Barker, Holly E. [1 ]
Bowtell, David D. [4 ]
Scott, Clare L. [1 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Melbourne, Parkville, Vic, Australia
[4] Peter MacCallum Canc Inst, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
    Evangelisti, Giulio
    Barra, Fabio
    Moioli, Melita
    Sala, Paolo
    Stigliani, Sara
    Gustavino, Claudio
    Costantini, Sergio
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 779 - 792
  • [42] DNA repair status of high-grade serous ovarian cancer change in a treatment course
    Takaya, Hisamitsu
    Nakai, Hidekatsu
    Sakai, Kazuko
    Nishio, Kazuto
    Matsumura, Noriomi
    CANCER SCIENCE, 2022, 113 : 363 - 363
  • [43] Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients
    Heinzelmann-Schwarz, V.
    Meszaros, A. Knipprath
    Stadlmann, S.
    Jacob, F.
    Schoetzau, A.
    Russell, K.
    Friedlander, M.
    Singer, G.
    Vetter, M.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 79 - 85
  • [44] CTDNA PROFILING TO PREDICT PROGNOSIS AND OPTIMIZE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER
    Oikkonen, Jaana
    Zhang, Kaiyang
    Salminen, Liina
    Huhtinen, Kaisa
    Schulman, Ingrid
    Andersson, Noora
    Carpen, Olli
    Hietanen, Sakari
    Grenman, Seija
    Lehtonen, Rainer
    Hynninen, Johanna
    Farkkila, Anniina
    Hautaniemi, Sampsa
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 106 - 106
  • [45] Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer
    Oikkonen, Jaana
    Li, Yilin
    Alkodsi, Amjad
    Carpen, Olli
    Huhtinen, Kaisa
    Hietanen, Sakari
    Grenman, Seija E.
    Lehtonen, Rainer
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2018, 78 (13)
  • [46] WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
    Yu, Hai-Lan
    Ma, Xu-Dong
    Tong, Jin-Fei
    Li, Jian-Qiong
    Guan, Xiao-Jing
    Yang, Jian-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 6191 - 6201
  • [47] Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
    Lana E. Kandalaft
    Denarda Dangaj Laniti
    George Coukos
    Nature Reviews Cancer, 2022, 22 : 640 - 656
  • [48] Role of integrins in the metastatic spread of high-grade serous ovarian cancer
    Slavomir Krajnak
    Jörg Jäkel
    Katharina Anić
    Roxana Schwab
    Marcus Schmidt
    Annette Hasenburg
    Wilfried Roth
    Walburgis Brenner
    Marco Johannes Battista
    Archives of Gynecology and Obstetrics, 2022, 305 : 1291 - 1298
  • [49] High-grade serous ovarian cancer (HGSOC) with fallopian tube involvement
    Tanase, Adina Elena
    Solomon-condriuc, Iustina Petra
    Mogos, Raluca Anamaria
    Costachescu, Gabriel
    David, Cristina
    Buzduga, Catalin Mihai
    Scripcariu, Dragos Viorel
    Costea, Claudia Florida
    Cucu, Andrei Ionut
    Tanase, Gabriel Valentin
    Tanase, Daniela Maria
    Nemescu, Dragos
    Dumitrescu, Ana Maria
    Carauleanu, Alexandru
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2024, 65 (02): : 325 - 329
  • [50] Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
    Sanders, Brooke E.
    Yamamoto, Tomomi M.
    McMellen, Alexandra
    Woodruff, Elizabeth R.
    Berning, Amber
    Post, Miriam D.
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (08) : 1285 - 1295
12345